AMADIS
Amadis , a leading payment software and consulting provider, today announced a partnership agreement with Softpay.io to provide its Universal EMV Level 2 Framework & pre-certified Kernels for integration into Softpay’s new Tap-to-Pay service. Softpay’s revolutionary Tap-to-Pay service can be downloaded into any Android device and turn into a full payment card acceptance terminal. Softpay’s solution provides merchants with greater flexibility and future proofing capabilities, while lowering costs and creating new revenue opportunities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220430005009/en/
The Amadis solution is a component of its Amadis One software framework composed of an EMV L2 Framework and ecosystem supporting any EMV Contactless Kernel. It enables Softpay’s service to seamlessly accept EMV payments on Android-based COTS devices with NFC capabilities, reduces the time for Softpay to roll out new products and provide payment acceptance of any payment schemes, on its new mobile payments platform. Amadis One software framework is the first solution to enable nexo (ISO 202022) standards on Tap-to-Pay platforms.
“Softpay’s solution helps us to transform the shopping experience, enabling our store associates to check out customers anywhere in-store, or at curbside,” said Thomas Grane, CIO, at Matas. “The solution drives new sales opportunities, and enables a more efficient, personalized customer experience.”
Softpay’s Tap-to-Pay is impacting several industries, including retailers and QSRs, who can operate more efficiently. Staff can accept payments, while multi-tasking anywhere in-store, or at curbside pickup locations. Transit companies can drive new points of sale by instantly offering and processing new and upgraded tickets, while passengers are on board trains and buses.
“Softpay’s Tap-to-Pay service provides innovative new experiences to retail, transportation and the QSR industries, and our Amadis One software framework helps them bring products to market faster,” said Emmanuel Haydont, CEO and co-founder, Amadis. “Amadis One commoditizes complex payment processes, freeing up resources for merchants to innovate, accelerating time to market and reducing costs, while enhancing the customer experience.”
“By integrating Amadis One with our Tap-to-Pay solution, we enable merchants to revolutionize the customer experience, while lowering their costs and providing greater flexibility,” said Craig Jacoby, CEO, Softpay.io. “By enabling tap-to-pay transactions on smartphones, merchant fees for card present transactions are lowered, new customer points of interactions (POIs) are generated, creating innovative new ways to interact with customers, while processing transactions.”
About Softpay.io
Softpay was founded in 2019 to take advantage of the new Visa and Mastercard specifications for payment terminals which enabled Softpay to develop a mobile application that allows merchants to turn a regular phone into a contactless payment terminal with PIN. Softpay has grown into a company with more than 30 employees and is headquartered in Copenhagen, Denmark. Softpay has received more than €9 mill in funding and the ambition is to be one of the leading global providers of tap-to-phone solutions. Leading European payment companies have decided to partner with Softpay and Softpay is now focusing on North America as well.
About Amadis
Amadis is a leader in payment card acceptance software technology, with its software running on more than 50 million devices worldwide. The company provides state-of-the-art software products, frameworks and solutions for global merchants, payment terminal manufacturers and payment processors. Amadis provides merchants with the industry’s broadest range of EMV card processing options using custom or commercially available technology, independent of hardware, operating system or geography. The company brings an elite, experienced software team to the industry and enables solutions for international acceptors in over 23 countries. Learn more at www.amadis.ca .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220430005009/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom